- Target
- PRAME
- Reactivity
- Human
- Application
- WB
- MW(Calculated)
- 56kD
- MW(Observed)
- --
- Host Species
- Rabbit
- Isotype
- IgG
- Conjugate/Modification
- Unmodified
- Modification site
- --
- Recommended Dilution Ratio
- WB 1:500-2000
- Form
- Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
- Source
- --
- Purification
- The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
- Purity
- --
- storageCondition
- -15°C to -25°C/1 year(Do not lower than -25°C)
- Concentration
- 1 mg/ml
- Clonality
- Polyclonal
- Clone No.
- --
- Immunogen
- Synthesized peptide derived from human PRAME
- Sequence
- --
- Specificity
- This antibody detects endogenous levels of PRAME at Human
- Gene Name
- PRAME MAPE OIP4
- Protein Name
- Melanoma antigen preferentially expressed in tumors (Opa-interacting protein 4) (OIP-4) (Preferentially expressed antigen of melanoma)
- Other Name
- --
- Organism-1
- Human
- Gene ID-1
- 23532
- SwissProt-1
- P78395
- Organism-2
- --
- Gene ID-2
- --
- SwissProt-2
- --
- Organism-3
- --
- Gene ID-3
- --
- SwissProt-3
- --
- Organism-4
- --
- gene ID-4
- --
- SwissProt-4
- --
- Cellular Localization
- Nucleus . Chromosome . Cytoplasm . Golgi apparatus . Cell membrane . Associates with chromatin; specifically enriched at transcriptionally active promoters that are also bound by nuclear transcription factor Y (composed of NFYA, NFYB and NFYC) and at enhancers (PubMed:21822215). Recruited to the Golgi apparatus in response to interferon gamma (IFNG) treatment (PubMed:23460923). .